Benzoyl peroxide/tretinoin

Drug Profile

Benzoyl peroxide/tretinoin

Alternative Names: S6G5T 1/S6G5T 3; TWIN

Latest Information Update: 03 Oct 2016

Price : $50

At a glance

  • Originator Sol-Gel Technologies
  • Developer Accelovance; Sol-Gel Technologies
  • Class Anti-infectives; Antiacnes; Benzoic acids; Keratolytics; Oxidants; Retinoids; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acne vulgaris

Most Recent Events

  • 01 May 2016 Phase-II clinical trials in Acne vulgaris in USA (Topical) (NCT02661958)
  • 15 Mar 2016 Biomarkers information updated
  • 04 Feb 2016 Sol-Gel Technologies plans a phase II trial for Acne vulgaris in USA (Topical, Cream) (NCT02661958)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top